Dexamethasone intravitreal implant in the treatment of diabetic macular edema

References

• KleinRKleinBEMossSEDavisMDDeMetsDLThe Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edemaOphthalmology19849112146414746521986
   PubMed Web of Science ®Google Scholar
• AntcliffRJMarshallJThe pathogenesis of edema in diabetic maculopathySemin Ophthalmol199914422323210758223
   PubMedGoogle Scholar
• BhagatNGrigorianRATutelaAZarbinMADiabetic macular edema: pathogenesis and treatmentSurv Ophthalmol200954113219171208
   PubMed Web of Science ®Google Scholar
• YauJWRogersSLKawasakiRMeta-Analysis for Eye Disease (META-EYE) Study GroupGlobal prevalence and major risk factors of diabetic retinopathyDiabetes Care201235355656422301125
   PubMed Web of Science ®Google Scholar
• FordJALoisNRoylePClarCShyangdanDWaughNCurrent treatments in diabetic macular oedema: systematic review and meta-analysisBMJ Open201333e002269
   PubMed Web of Science ®Google Scholar
• ZhangWLiuHAl-ShabraweyMCaldwellRWCaldwellRBInflammation and diabetic retinal microvascular complicationsJ Cardiovasc Dis Res2011229610321814413
   PubMedGoogle Scholar
• EhrlichRHarrisACiullaTAKheradiyaNWinstonDMWirostkoBDiabetic macular oedema: physical, physiological and molecular factors contribute to this pathological processActa Ophthalmol201088327929120222885
   PubMed Web of Science ®Google Scholar
• The Diabetes Control and Complications Trial Research GroupThe effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitusN Engl J Med1993329149779868366922
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet199835291318378539742976
   PubMed Web of Science ®Google Scholar
• AntonettiDABarberAJBronsonSKJDRF Diabetic Retinopathy Center GroupDiabetic retinopathy: seeing beyond glucose-induced microvascular diseaseDiabetes20065592401241116936187
   PubMed Web of Science ®Google Scholar
• SchollSAugustinALoewensteinARizzoSKuppermanBGeneral pathophysiology of macular edemaEur J Ophthalmol201121suppl 6S10S1923264324
   PubMed Web of Science ®Google Scholar
• StewartMWCorticosteroid use for diabetic macular edema: old fad or new trend?Curr Diab Rep201212436437522581206
   PubMed Web of Science ®Google Scholar
• ZhangWLiuHRojasMCaldwellRWCaldwellRBAnti-inflammatory therapy for diabetic retinopathyImmunotherapy20113560962821554091
   PubMed Web of Science ®Google Scholar
• FunatsuHNomaHMimuraTEguchiSHoriSAssociation of vitreous inflammatory factors with diabetic macular edemaOphthalmology20091161737919118698
   PubMed Web of Science ®Google Scholar
• YoshimuraTSonodaKHSugaharaMComprehensive analysis of inflammatory immune mediators in vitreoretinal diseasesPLoS One2009412e815819997642
   PubMed Web of Science ®Google Scholar
• El-AsrarAMNawazMIKangaveDHigh-mobility group box-1 and biomarkers of inflammation in the vitreous from patients with proliferative diabetic retinopathyMol Vis2011171829183821850157
   PubMed Web of Science ®Google Scholar
• Adamiec-MroczekJOficjalska-MlyńczakJMisiuk-HojłoMRoles of endothelin-1 and selected proinflammatory cytokines in the pathogenesis of proliferative diabetic retinopathy: analysis of vitreous samplesCytokine201049326927420015663
   PubMed Web of Science ®Google Scholar
• MaierRWegerMHaller-SchoberEMMultiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patientsMol Vis20081463764318385799
   PubMed Web of Science ®Google Scholar
• LeeWJKangMHSeongMChoHYComparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular oedema and macular oedema due to branch retinal vein occlusionBr J Ophthalmol201296111426143022930681
   PubMed Web of Science ®Google Scholar
• MiyamotoKOguraYPathogenetic potential of leukocytes in diabetic retinopathySemin Ophthalmol199914423323910758224
   PubMedGoogle Scholar
• GardnerTWAntonettiDABarberAJLaNoueKFLevisonSWDiabetic retinopathy: more than meets the eyeSurv Ophthalmol200247suppl 2S253S26212507627
   PubMed Web of Science ®Google Scholar
• JoussenAMPoulakiVLeMLA central role for inflammation in the pathogenesis of diabetic retinopathyFASEB J200418121450145215231732
   PubMed Web of Science ®Google Scholar
• TangJKernTSInflammation in diabetic retinopathyProg Retin Eye Res201130534335821635964
   PubMed Web of Science ®Google Scholar
• BrucklacherRMPatelKMVanGuilderHDWhole genome assessment of the retinal response to diabetes reveals a progressive neurovascular inflammatory responseBMC Med Genomics200812618554398
   PubMed Web of Science ®Google Scholar
• JoussenAMPoulakiVMitsiadesNSuppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetesFASEB J2003171767812475915
   PubMed Web of Science ®Google Scholar
• RojasMZhangWXuZRequirement of NOX2 expression in both retina and bone marrow for diabetes-induced retinal vascular injuryPLoS One2013812e8435724358357
   PubMed Web of Science ®Google Scholar
• DeisslerHLDeisslerHLangGKLangGEVEGF but not PlGF disturbs the barrier of retinal endothelial cellsExp Eye Res201311516217123891860
   PubMed Web of Science ®Google Scholar
• AveleiraCALinCMAbcouwerSFAmbrosioAFAntonettiDATNF-alpha signals through PKCzeta/NF-kappaB to alter the tight junction complex and increase retinal endothelial cell permeabilityDiabetes201059112872288220693346
   PubMed Web of Science ®Google Scholar
• LealECManivannanAHosoyaKInducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathyInvest Ophthalmol Vis Sci200748115257526517962481
   PubMed Web of Science ®Google Scholar
• AntonettiDALiethEBarberAJGardnerTWMolecular mechanisms of vascular permeability in diabetic retinopathySemin Ophthalmol199914424024810758225
   PubMedGoogle Scholar
• BarberAJAntonettiDAMapping the blood vessels with paracellular permeability in the retinas of diabetic ratsInvest Ophthalmol Vis Sci200344125410541614638745
   PubMed Web of Science ®Google Scholar
• BoltonSJAnthonyDCPerryVHLoss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivoNeuroscience1998864124512579697130
   PubMed Web of Science ®Google Scholar
• RangasamySMcGuirePGDasADiabetic retinopathy and inflammation: novel therapeutic targetsMiddle East Afr J Ophthalmol2012191525922346115
   PubMedGoogle Scholar
• EdelmanJLDifferentiating intraocular glucocorticoidsOphthalmologica2010224suppl 1253020714178
   PubMed Web of Science ®Google Scholar
• ClarkARBelvisiMGMaps and legends: the quest for dissociated ligands of the glucocorticoid receptorPharmacol Ther20121341546722212616
   PubMed Web of Science ®Google Scholar
• BusilloJMCidlowskiJAThe five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restoreTrends Endocrinol Metab201324310911923312823
   PubMed Web of Science ®Google Scholar
• SolitoEMullaAMorrisJFChristianHCFlowerRJBuckinghamJCDexamethasone induces rapid serine-phosphorylation and membrane translocation of annexin 1 in a human folliculostellate cell line via a novel nongenomic mechanism involving the glucocorticoid receptor, protein kinase C, phosphatidylinositol 3-kinase, and mitogen-activated protein kinaseEndocrinology200314441164117412639897
   PubMed Web of Science ®Google Scholar
• DalliJNorlingLVRenshawDCooperDLeungKYPerrettiMAnnexin 1 mediates the rapid anti-inflammatory effects of neutrophil-derived microparticlesBlood200811262512251918594025
   PubMed Web of Science ®Google Scholar
• LogieJJAliSMarshallKMHeckMMWalkerBRHadokePWGlucocorticoid-mediated inhibition of angiogenic changes in human endothelial cells is not caused by reductions in cell proliferation or migrationPLoS One2010512e1447621217824
   PubMed Web of Science ®Google Scholar
• GongYJinXWangQSThe involvement of high mobility group 1 cytokine and phospholipases A2 in diabetic retinopathyLipid Health Dis201413156
   PubMed Web of Science ®Google Scholar
• LupoGMottaCGiurdanellaGRole of phospholipases A2 in diabetic retinopathy: in vitro and in vivo studiesBiochem Pharmacol201386111603161324076420
   PubMed Web of Science ®Google Scholar
• PannickeTIandievIWurmADiabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retinaDiabetes200655363363916505225
   PubMed Web of Science ®Google Scholar
• TamuraHMiyamotoKKiryuJIntravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retinaInvest Ophthalmol Vis Sci20054641440144415790913
   PubMed Web of Science ®Google Scholar
• MiuraYRoiderJTriamcinolone acetonide prevents oxidative stress-induced tight junction disruption of retinal pigment epithelial cellsGraefes Arch Clin Exp Ophthalmol2009247564164919189116
   PubMed Web of Science ®Google Scholar
• ReichenbachAWurmAPannickeTIandievIWiedemannPBringmannAMuller cells as players in retinal degeneration and edemaGraefes Arch Clinical Exp Ophthalmol2007245562763617219109
   PubMed Web of Science ®Google Scholar
• ZhaoMBousquetEValamaneshFDifferential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retinaInvest Ophthalmol Vis Sci20115296340634721724913
   PubMed Web of Science ®Google Scholar
• HughesPMOlejnikOChang-LinJEWilsonCGTopical and systemic drug delivery to the posterior segmentsAdv Drug Deliv Rev200557142010203216289435
   PubMed Web of Science ®Google Scholar
• EdelhauserHFRowe-RendlemanCLRobinsonMROphthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applicationsInvest Ophthalmol Vis Sci201051115403542020980702
   PubMed Web of Science ®Google Scholar
• MauriceDMDrug delivery to the posterior segment from dropsSurv Ophthalmol200247suppl 1S41S5212204700
   PubMed Web of Science ®Google Scholar
• KimSHLutzRJWangNSRobinsonMRTransport barriers in transscleral drug delivery for retinal diseasesOphthalmic Res200739524425417851264
   PubMed Web of Science ®Google Scholar
• JagerRDAielloLPPatelSCCunninghamETJrRisks of intravitreous injection: a comprehensive reviewRetina200424567669815492621
   PubMed Web of Science ®Google Scholar
• KwakHWD’AmicoDJEvaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injectionArch Ophthalmol199211022592661736876
   PubMed Web of Science ®Google Scholar
• KaurIPKakkarSNanotherapy for posterior eye diseasesJ Control Release201419310011224862316
   PubMed Web of Science ®Google Scholar
• YasukawaTOguraYTabataYKimuraHWiedemannPHondaYDrug delivery systems for vitreoretinal diseasesProg Retin Eye Res200423325328115177203
   PubMed Web of Science ®Google Scholar
• MoisseievERegenbogenMRabinovitchTBarakALoewensteinAGoldsteinMEvaluation of pain during intravitreal Ozurdex injections vs intravitreal bevacizumab injectionsEye201428898098524924442
   PubMed Web of Science ®Google Scholar
• MeyerCHKleinAAltenFRelease and velocity of micronized dexamethasone implants with an intravitreal drug delivery system: kinematic analysis with a high-speed cameraRetina201232102133214023060033
   PubMed Web of Science ®Google Scholar
• BerarducciASianISLingRInadvertent dexamethasone implant injection into the lens body managementEur J Ophthalmol201424462062224519508
   PubMed Web of Science ®Google Scholar
• Coca-RobinotJCasco-SilvaBArmada-MarescaFGarcia-MartinezJAccidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lensEur J Ophthalmol201424463363624519506
   PubMed Web of Science ®Google Scholar
• FasceFBattaglia ParodiMKnutssonKAAccidental injection of dexamethasone intravitreal implant in the crystalline lensActa Ophthalmol2014924e330e33124373603
   PubMed Web of Science ®Google Scholar
• AgrawalRFernandez-SanzGBalaSAddisonPKDesegmentation of Ozurdex implant in vitreous cavity: report of two casesBr J Ophthalmol201498796196324648417
   PubMed Web of Science ®Google Scholar
• DonmezOParlakMYamanASaatciAOSplitting of a dexametha-sone implant (Ozurdex) following the injectionCase Rep Ophthalmol Med2013201324794923984139
   PubMedGoogle Scholar
• RoyRHegdeSSplit Ozurdex implant: a cautionCan J Ophthalmol2013481e15e1623419308
   PubMed Web of Science ®Google Scholar
• RishiPMathurGRishiEFractured Ozurdex™ implant in the vitreous cavityInd J Ophthalmol2012604337338
   PubMed Web of Science ®Google Scholar
• Wai Ch’ngSPadroniSBanerjeeSAnterior vitreous displacement of the intravitreal dexamethasone implant (Ozurdex)Eye201428223823924336298
   PubMed Web of Science ®Google Scholar
• KhuranaRNAppaSNMcCannelCADexamethasone implant anterior chamber migration: risk factors, complications, and management strategiesOphthalmology20141211677123890421
   PubMed Web of Science ®Google Scholar
• KishoreSASchaalSManagement of anterior chamber dislocation of dexamethasone implantOcul Immunol Inflamm2013211909123323589
   PubMed Web of Science ®Google Scholar
• VelaJICrespiJAndreuDRepositioning of dexamethasone intravitreal implant (Ozurdex) migrated into the anterior chamberIntl Ophthalmol2012326583584
   Google Scholar
• BansalRBansalPKulkarniPGuptaVSharmaAGuptaAWandering Ozurdex(®) implantJ Ophthalmic Inflamm Infect2012211521960148
   PubMedGoogle Scholar
• MalclèsAJanin-ManificatHYhuelYAnterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three casesJ Franc Ophtalmol2013364362367 French
   Web of Science ®Google Scholar
• Chang-LinJEAttarMAcheampongAAPharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implantInvest Ophthalmol Vis Sci2011521808620702826
   PubMed Web of Science ®Google Scholar
• Chang-LinJEBurkeJAPengQPharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvit-rectomized eyesInvest Ophthalmol Vis Sci20115274605460921421864
   PubMed Web of Science ®Google Scholar
• WeijtensOFeronEJSchoemakerRCHigh concentration of dexamethasone in aqueous and vitreous after subconjunctival injectionAm J Ophthalmol1999128219219710458175
   PubMed Web of Science ®Google Scholar
• WeijtensOvan der SluijsFASchoemakerRCPeribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injectionAm J Ophthalmol199712333583639063245
   PubMed Web of Science ®Google Scholar
• WeijtensOSchoemakerRCRomijnFPCohenAFLentjesEGvan MeursJCIntraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphateOphthalmology2002109101887189112359610
   PubMed Web of Science ®Google Scholar
• WeijtensOSchoemakerRCCohenAFDexamethasone concentration in vitreous and serum after oral administrationAm J Ophthalmol199812556736799625551
   PubMed Web of Science ®Google Scholar
• ChinHSParkTSMoonYSOhJHDifference in clearance of intra-vitreal triamcinolone acetonide between vitrectomized and nonvitrec-tomized eyesRetina200525555656016077349
   PubMed Web of Science ®Google Scholar
• HallerJAKuppermannBDBlumenkranzMSDexamethasone DDS Phase II Study GroupRandomized controlled trial of an intrav-itreous dexamethasone drug delivery system in patients with diabetic macular edemaArch Ophthalmol2010128328929620212197
   PubMed Web of Science ®Google Scholar
• KuppermannBDChouCWeinbergDVWhitcupSMHallerJABlumenkranzMSIntravitreous dexamethasone effects on different patterns of diabetic macular edemaArch Ophthalmol2010128564264320212194
   PubMedGoogle Scholar
• BeerPMBakriSJSinghRJLiuWPetersGB3rdMillerMIntraocu-lar concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injectionOphthalmology2003110468168612689886
   PubMed Web of Science ®Google Scholar
• BoyerDSFaberDGuptaSOzurdex CHAMPLAIN Study GroupDexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patientsRetina201131591592321487341
   PubMed Web of Science ®Google Scholar
• CallananDGGuptaSBoyerDSOzurdex PLACID Study GroupDexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edemaOphthalmology201312091843185123706947
   PubMed Web of Science ®Google Scholar
• BoyerDSYoonYHBelfortRJrThree-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edemaOphthalmology2014121101904191424907062
   PubMed Web of Science ®Google Scholar
• DanisRPSaddaSCuiHLiX-YHashadYWhitcupSMAnatomic outcomes with dexamethasone intravitreal implant in diabetic macular edema: a pooled analysis of two randomized Phase III trialsARVO 2014 Annual MeetingMay 4–8, 2014Orlando, FL
   Google Scholar
• SaddaSDanisRPLiX-YCuiHHashadYWhitcupSMAnatomic effects of dexamethasone intravitreal implant in diabetic macular edema: pooled analysis of findings from two randomized Phase 3 studies32nd Annual Meeting of the American Society of Retina SpecialistsAugust 9–13, 2014San Diego
   Google Scholar
• LazicRLukicMBorasITreatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implantRetina201434471972423975006
   PubMed Web of Science ®Google Scholar
• SorkinNLoewensteinAHabot-WilnerZGoldsteinMIntravitreal dexamethasone implant in patients with persistent macular edema of variable etiologiesOphthalmologica20142322839124942067
   PubMed Web of Science ®Google Scholar
• Dutra MedeirosMPostorinoMNavarroRGarcia-ArumiJMateoCCorcosteguiBDexamethasone intravitreal implant for treatment of patients with persistent diabetic macular edemaOphthalmologica2014231314114624356099
   PubMed Web of Science ®Google Scholar
• PacellaEVestriARMuscellaRPreliminary results of an intra-vitreal dexamethasone implant (Ozurdex®) in patients with persistent diabetic macular edemaClin Ophthalmol201371423142823901252
   PubMedGoogle Scholar
• ZucchiattiILattanzioRQuerquesGIntravitreal dexamethasone implant in patients with persistent diabetic macular edemaOphthalmologica2012228211712222310491
   PubMed Web of Science ®Google Scholar
• ThakurAKadamRKompellaUBTrabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataractsArch Ophthalmol2011129791492021402977
   PubMedGoogle Scholar
• AnonOzurdex Prescribing Information2014 Available from: http://www.allergan.com/assets/pdf/ozurdex_pi.pdfAccessed March 27, 2015
   Google Scholar
• CampochiaroPABrownDMPearsonAFAME Study GroupSustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edemaOphthalmology2012119102125213222727177
   PubMed Web of Science ®Google Scholar